<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29360932</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1569-8041</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
          <ISOAbbreviation>Ann Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.</ArticleTitle>
        <Pagination>
          <StartPage>888</StartPage>
          <EndPage>894</EndPage>
          <MedlinePgn>888-894</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdy012</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0923-7534(19)45462-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone).</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) MBC were randomized 2 : 1 to palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires.</AbstractText>
          <AbstractText Label="RESULTS">As of 26 February 2016, the median duration of follow-up was 23 months. Baseline scores were comparable between the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total, FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; P = 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression and patients with partial or complete response versus those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without neutropenia.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2- MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders. ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rugo</LastName>
            <ForeName>H S</ForeName>
            <Initials>HS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, USA. Electronic address: hope.rugo@ucsf.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diéras</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Institut Curie, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gelmon</LastName>
            <ForeName>K A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, British Columbia Cancer Agency-Vancouver Centre, Vancouver, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Finn</LastName>
            <ForeName>R S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, University of California, Los Angeles, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slamon</LastName>
            <ForeName>D J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, University of California, Los Angeles, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, GEICAM, Universidad Complutense, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neven</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Universitair Ziekenhuis Leuven-Campus Gasthuisberg, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shparyk</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemotherapy, Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mori</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Global Product Developmen, Clinical, Pfizer s.r.l., Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>D R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Global Product Developmen, Statistics, Pfizer Inc., La Jolla, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhattacharyya</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Biostatistics, Pfizer Inc., New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bartlett</LastName>
            <ForeName>C H U A N G</ForeName>
            <Initials>CHUANG</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Affairs, Pfizer Inc., New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iyer</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Global Outcomes and Evidence, Pfizer Inc., New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnston</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, The Royal Marsden NHS Foundation, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ettl</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Frauenklinik und Poliklinik Klinikum Rechts der Isar, Technische Universität München, München, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harbeck</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), München, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT01740427</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Oncol</MedlineTA>
        <NlmUniqueID>9007735</NlmUniqueID>
        <ISSNLinking>0923-7534</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Ann Oncol. 2018 Aug 1;29(8):1878</RefSource>
          <PMID Version="1">29873677</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Ann Oncol. 2018 Aug 1;29(8):1877</RefSource>
          <PMID Version="1">29873692</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29360932</ArticleId>
        <ArticleId IdType="pmc">PMC5913649</ArticleId>
        <ArticleId IdType="doi">10.1093/annonc/mdy012</ArticleId>
        <ArticleId IdType="pii">S0923-7534(19)45462-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Butters DJ, Ghersi D, Wilcken N. 
et al. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 2010; CD003368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7154379</ArticleId>
            <ArticleId IdType="pubmed">21069675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miles D, von Minckwitz G, Seidman AD.. 
Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002; 7(Suppl 6): 13–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12454315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Toogood PL, Harvey PJ, Repine JT. 
et al.
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48(7): 2388–2406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15801831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Finn RS, Martin M, Rugo HS. 
et al.
Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375(20): 1925–1936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27959613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brady MJ, Cella DF, Mo F. 
et al.
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15(3): 974–986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9060536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
EuroQoL Group.
EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3): 199–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10109801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou X, Cella D, Cameron D. 
et al.
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009; 117(3): 577–589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19153829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eton DT, Cella D, Yost KJ. 
et al.
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57(9): 898–910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15504633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fitzmaurice GM, Laird NM, Ware JH.. 
Applied Longitudinal Analysis. 
Hoboken, NJ: 
John Wiley &amp; Sons, 2011.</Citation>
        </Reference>
        <Reference>
          <Citation>
Brucker PS, Yost K, Cashy J. 
et al.
General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005; 28(2): 192–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harbeck N, Iyer S, Turner N. 
et al.
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 2016; 27(6): 1047–1054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4880065</ArticleId>
            <ArticleId IdType="pubmed">27029704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Campone M, Beck JT, Gnant M. 
et al.
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin 2013; 29(11): 1463–1473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23962028</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
